App aims to improve life for brain tumor patients

NCT ID NCT07439302

Not yet recruiting Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will test whether a mobile app called Resilience PRO can help monitor symptoms and quality of life in 80 adults with IDH-mutated glioma who are starting a new systemic treatment. Participants will use the app to report side effects and complete questionnaires every two weeks. The goal is to see if remote monitoring can catch problems early and improve care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Resilience PRO mobile app for symptom monitoring
What this could lead to: If successful, this could show that remote symptom tracking improves quality of life and reduces hospital visits for people with this type of brain tumor.
What could go wrong: This is an observational study, not a treatment trial. It may not prove that the app directly improves outcomes, and results may vary across different patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA ONCOLOGY

Contacts and locations

Locations

Service de Neuro-oncologie, Hôpital de la Pitié-Salpêtrière

Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.